Tag: John Orloff

Alexion discloses plan for CHAMPION-ALS clinical trial of ULTOMIRIS

pharmanewsdaily- January 15, 2020

Alexion Pharmaceuticals has revealed plans for initiating the CHAMPION-ALS clinical trial, a phase 3 study to evaluate ULTOMIRIS (ravulizumab) for the treatment of amyotrophic lateral ... Read More

Alexion Pharmaceuticals bags Ultomiris FDA approval for atypical HUS

pharmanewsdaily- October 21, 2019

Ultomiris FDA approval : Alexion Pharmaceuticals has bagged approval from the US Food and Drug Administration (FDA) for Ultomiris (ravulizumab-cwvz) for the treatment of atypical ... Read More

Alexion bags Ultomiris EU approval for paroxysmal nocturnal hemoglobinuria

pharmanewsdaily- July 5, 2019

Ultomiris EU approval : Alexion Pharmaceuticals has secured approval from the European Commission (EC) for its C5 complement inhibitor Ultomiris (ravulizumab) for the treatment of ... Read More